Recent Updates
Recently added Catalysts
RNXT Positive Sentiment

RenovoRx Updates Pivotal TIGeR-PaC Trial of Pancreatic Cancer Treatment

Wednesday, August 20, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: RenovoRx, Inc. has provided an update on its pivotal phase 3 TIGeR-PaC trial, which is assessing its investigational drug-device combination for treating locally advanced pancreatic cancer. The trial employs the TAMP transarterial microperfusion therapy platform using RenovoCath for administering gemcitabine. The study requires 114 randomized patients and 86 events for final analysis.
Price reaction · baseline $0.8349 (2025-08-20T14:05:00.000Z) · hit during market hours · clean, no other RNXT news in the window
day 0 close · peak
+4.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • RenovoRx is advancing its pivotal phase 3 TIGeR-PaC trial.
  • The trial focuses on a novel treatment for pancreatic cancer.
  • The investigational drug-device combination shows promise.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
12.3%
average across 4 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
nab-paclitaxel
Phase 3 · Locally Advanced Pancreatic Cancer

Full Press Release Details

RenovoRx, Inc. announced an update of its ongoing pivotal phase 3 TIGeR-PaC trial , which is evaluating the company’s first investigational drug-device combination oncology product candidate, which uses RenovoRx’s TAMP transarterial microperfusion therapy platform enabled by its RenovoCath for the treatment of locally advanced pancreatic cancer.
The combination product candidate utilizes RenovoCath for the intra-arterial administration of the chemotherapy gemcitabine, noted RenovoRx.
The company stated that the current protocol and statistical analysis plan for the TIGeR-PaC trial requires 114 randomized patients, with 86 events—deaths—necessary to complete the final analysis.
Read More on Endovascular Today

Frequently Asked Questions

What is the TIGeR-PaC trial?

The TIGeR-PaC trial is a pivotal phase 3 study evaluating RenovoRx's drug-device combination for pancreatic cancer.

What does the RenovoCath do?

RenovoCath is used for intra-arterial administration of the chemotherapy gemcitabine.

How many patients are needed for the trial?

The trial requires 114 randomized patients to complete the final analysis.

What is the primary focus of the TIGeR-PaC trial?

The trial focuses on treating locally advanced pancreatic cancer.

ShareAdd on Google
Tags: RNXT Viatris Investor Conferences Healthcare RenovoRx pancreatic cancer TIGeR-PaC gemcitabine clinical trial
Last updated: Aug 20, 2025

Biotech snapshot

Cash runway
$9M liquidity · $1M/mo burn
~10 mo
Medium dilution risk
Lead asset
nab-paclitaxelPhase 3
Locally Advanced Pancreatic Cancer →

Catalyst track record

+57%
best trade around RNXT's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for RNXT.

See every catalyst's timing & PoA →